Xenetic Biosciences, Inc. (XBIO)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 1.5M 3M 4.5M Q3 '12: 112.8K Q4 '12: 132K Q1 '13: 128.6K Q2 '13: 131.6K Q2 '19: 0 Q3 '19: 0 Q4 '19: 17.1K Q1 '20: 73.8K Q2 '20: 186.7K Q3 '20: 302.7K Q4 '20: 436.9K Q1 '21: 571.4K Q2 '21: 746.1K Q3 '21: 979.4K Q4 '21: 1.2M Q1 '22: 1.4M Q2 '22: 1.5M Q3 '22: 1.6M Q4 '22: 1.7M Q1 '23: 1.9M Q2 '23: 2.2M Q3 '23: 2.4M Q4 '23: 2.5M Q1 '24: 2.4M Q2 '24: 2.5M Q3 '24: 2.5M Q4 '24: 2.5M Q1 '25: 2.6M Q2 '25: 2.4M Q3 '25: 2.9M Q4 '25: 3M Q1 '26: 3.2M Q2 '26: 3.3M Q1 '13 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit TTM

0 350K 700K 1.1M Q1 '14: 1M Q1 '14

Operating Income TTM

-60M -40M -20M 0 20M 40M 60M Q3 '12: -116.7K Q4 '12: -113.1K Q1 '13: -68.8K Q3 '14: -12.3M Q4 '14: -12.9M Q1 '15: -11.9M Q2 '15: -10.7M Q3 '15: -11.3M Q4 '15: -9.8M Q1 '16: -9.7M Q2 '16: -51.6M Q3 '16: -50.1M Q4 '16: -47.4M Q1 '17: -48.4M Q2 '17: -8.1M Q3 '17: -8.1M Q4 '17: -3.6M Q1 '18: -2.5M Q2 '18: -1.6M Q3 '18: -1.2M Q4 '18: -7.3M Q1 '19: -6.8M Q2 '19: -6.2M Q3 '19: -13.3M Q4 '19: -12.9M Q1 '20: -12.8M Q2 '20: -12.4M Q3 '20: -14M Q4 '20: -13.9M Q1 '21: -14.1M Q2 '21: -14.2M Q3 '21: -5.1M Q4 '21: -5.7M Q1 '22: -6M Q2 '22: -7.6M Q3 '22: -7M Q4 '22: -6.7M Q1 '23: -6M Q2 '23: -4.5M Q3 '23: -4.8M Q4 '23: -4.5M Q1 '24: -4.9M Q2 '24: -5M Q3 '24: -4.4M Q4 '24: -4.2M Q1 '25: -3.9M Q2 '25: -3.3M Q3 '25: -3.3M Q4 '25: -2.8M Q1 '26: -2.4M Q2 '26: -2.6M Q4 '12 Q4 '15 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

Net Income TTM

-75M -50M -25M 0 25M 50M 75M Q3 '12: -89.2K Q4 '12: -85.5K Q1 '13: -41.1K Q3 '14: -13.5M Q4 '14: -14.3M Q1 '15: -12.7M Q2 '15: -11M Q3 '15: -13.2M Q4 '15: -12.5M Q1 '16: -13.6M Q2 '16: -60.3M Q3 '16: -57.4M Q4 '16: -54.2M Q1 '17: -53.5M Q2 '17: -8.6M Q3 '17: -8.4M Q4 '17: -3.6M Q1 '18: -2.6M Q2 '18: -1.7M Q3 '18: -1.2M Q4 '18: -7.3M Q1 '19: -6.8M Q2 '19: -6.2M Q3 '19: -13.2M Q4 '19: -12.8M Q1 '20: -12.6M Q2 '20: -12.2M Q3 '20: -10.9M Q4 '20: -10.9M Q1 '21: -11.1M Q2 '21: -11.2M Q3 '21: -5M Q4 '21: -5.6M Q1 '22: -5.9M Q2 '22: -7.5M Q3 '22: -6.9M Q4 '22: -6.6M Q1 '23: -5.8M Q2 '23: -4.2M Q3 '23: -4.4M Q4 '23: -4.1M Q1 '24: -4.5M Q2 '24: -4.7M Q3 '24: -4.1M Q4 '24: -4M Q1 '25: -3.7M Q2 '25: -3.1M Q3 '25: -3.2M Q4 '25: -2.7M Q1 '26: -2.2M Q2 '26: -2.5M Q4 '12 Q4 '15 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-15M -10M -5M 0 5M 10M 15M Q3 '12: -13K Q3 '14: -12M Q4 '14: -12.7M Q1 '15: -10.6M Q2 '15: -7.6M Q3 '15: -6.8M Q4 '15: -5.3M Q1 '16: -5M Q2 '16: -6.2M Q3 '16: -5.3M Q4 '16: -8.8M Q1 '17: -6.7M Q2 '17: -7.4M Q3 '17: -8M Q4 '17: 1.5M Q1 '18: -453.4K Q2 '18: -553.8K Q3 '18: -584.8K Q4 '18: -6.5M Q1 '19: -6.1M Q2 '19: -5M Q3 '19: -5.8M Q4 '19: -6.4M Q1 '20: -6.1M Q2 '20: -6.4M Q3 '20: -5M Q4 '20: -4.3M Q1 '21: -4.8M Q2 '21: -4.2M Q3 '21: -4.2M Q4 '21: -4.7M Q1 '22: -5.3M Q2 '22: -5.3M Q3 '22: -5.4M Q4 '22: -4.6M Q1 '23: -3.7M Q2 '23: -4.2M Q3 '23: -4.1M Q4 '23: -4.1M Q1 '24: -4.2M Q2 '24: -3.4M Q3 '24: -2.9M Q4 '24: -2.8M Q1 '25: -2.7M Q2 '25: -2.5M Q3 '25: -2.7M Q4 '25: -2.3M Q1 '26: -1.8M Q2 '26: -2.3M Q4 '15 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

Free Cash Flow TTM

-15M -10M -5M 0 5M 10M 15M Q3 '14: -12.1M Q4 '14: -12.7M Q1 '15: -10.6M Q2 '15: -7.6M Q3 '15: -6.9M Q4 '15: -5.3M Q1 '16: -5.1M Q2 '16: -6.2M Q3 '16: -5.3M Q4 '16: -8.8M Q1 '17: -6.7M Q2 '17: -7.4M Q3 '17: -8M Q4 '17: 1.5M Q1 '18: -457.3K Q2 '18: -553.8K Q3 '18: -584.8K Q4 '18: -6.5M Q1 '15 Q4 '15 Q3 '16 Q2 '17 Q1 '18 Q4 '18

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 50M 100M 150M Q4 '11: 10M Q1 '12: 100M Q2 '12: 121.3M Q4 '12: 13.5M Q1 '13: 135M Q2 '13: 135M Q4 '13: 135M Q2 '21: 8.7M Q3 '21: 10.2M Q1 '22: 13.4M Q2 '22: 1.4M Q3 '22: 1.4M Q1 '23: 1.5M Q2 '23: 1.5M Q3 '23: 1.5M Q1 '24: 1.5M Q2 '24: 1.5M Q3 '24: 1.5M Q1 '25: 1.5M Q2 '25: 1.5M Q3 '25: 1.5M Q1 '26: 2.3M Q2 '26: 2.3M Q1 '12 Q1 '13 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-15.00 -10.00 -5.00 0.00 5.00 10.00 15.00 Q3 '12: -0.01 Q4 '12: -0.01 Q1 '13: -0.01 Q3 '14: -0.10 Q4 '14: -0.11 Q1 '15: -0.10 Q2 '15: -0.35 Q3 '15: -1.59 Q4 '15: -2.41 Q1 '16: -3.17 Q2 '16: -9.02 Q3 '16: -8.04 Q4 '16: -7.84 Q1 '17: -7.40 Q2 '17: -1.62 Q3 '17: -1.60 Q4 '17: -0.41 Q1 '18: -0.28 Q2 '18: -2.72 Q3 '18: -4.77 Q4 '18: -7.38 Q1 '19: -13.62 Q2 '19: -12.40 Q3 '19: -12.76 Q4 '19: -6.33 Q1 '20: -0.07 Q2 '20: 1.34 Q3 '20: 2.81 Q4 '20: -1.69 Q1 '21: -1.65 Q2 '21: -1.63 Q3 '21: -0.56 Q4 '21: -0.55 Q1 '22: -0.52 Q2 '22: -2.29 Q3 '22: -2.72 Q4 '22: -3.55 Q1 '23: -3.99 Q2 '23: -2.78 Q3 '23: -2.91 Q4 '23: -2.71 Q1 '24: -2.93 Q2 '24: -3.07 Q3 '24: -2.66 Q4 '24: -2.57 Q1 '25: -2.38 Q2 '25: -2.00 Q3 '25: -2.05 Q4 '25: -1.59 Q1 '26: -1.20 Q2 '26: -1.16 Q4 '12 Q4 '15 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.